FDA Approves Lilly’s Inluriyo and Verzenio Combination for ESR1-Mutated Breast Cancer
Oncology FDA Approves Lilly’s Inluriyo Plus Verzenio for ESR1-Mutated Breast Cancer The all-oral combination doubled median progression-free survival in a key trial subgroup. Here’s how it works, who it’s for, and what